Epilepsy & Seizures

Latest News

Quality of Life and Seizure Improvement With Clobazam for Lennox-Gastaut Syndrome

Clobazam, as an adjunct therapy, improved symptoms and quality of life for children with Lennox-Gastaut syndrome.

One-Third of Epilepsy Cases Go Untreated up to 3 Years After Diagnosis

This gap in treatment may be increasing the risk for medical events and hospitalization in these patients.

FDA Approves Nayzilam Nasal Spray to Treat Seizure Clusters

The Food and Drug Administration (FDA) has approved Nayzilam (midazolam) nasal spray for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity.

Treatment of Epilepsy in Pregnancy Varies Across Geographic Settings

Refined guidelines may benefit the treatment and monitoring of epilepsy in pregnant women.

Temporal Lobe Epilepsy Phenotypes Associated With White Matter Covariance

Different cognitive phenotypes based on neuropsychological measures of language and memory are associated with distinct patterns of white matter abnormalities in patients with temporal lobe epilepsy.

Focal Surgery Linked to Modest IQ Improvements in Children With Epilepsy

Investigators analyzed clinical and neuroimaging factors related to cognitive outcome after epilepsy surgery in childhood.

Vagus Nerve Stimulation Beneficial in Epilepsy and Comorbid Depression

Findings suggest VNS to be effective in the treatment of epilepsy and comorbid depression.

Are Febrile Seizures Associated With Increased Sudden Death Risk in Young Children?

Recent data suggest that FS may contribute to sudden unexplained death in childhood.

Effectiveness of Responsive Neurostimulation Modulated by Seizure Network Activity

Investigators sought to determine the relationship between electrographic effects of responsive neurostimulation, established in electrocorticographic recordings from the device, and patient outcomes.

High-Dose Oral Vitamin D3 Appears Safe and Well-Tolerated in Epilepsy

Investigators evaluated the safety and tolerability of oral Vitamin D3 5000 IU/d in patients with drug-resistant epilepsy.